← Back to Search

Hormone Therapy

Sleep Treatments for Long COVID Syndrome

Phase 2
Recruiting
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥ 18 years of age at the time of enrollment
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This trial is looking at different interventions to help improve sleep problems in patients with Post-Acute Sequelae of SARS-CoV-2 (PASC). The trial uses a flexible protocol that

Who is the study for?
This trial is for adults over 18 who've had COVID-19 and are now experiencing new or worsened sleep problems lasting at least 12 weeks. Participants must have been in contact with a COVID case, hospitalized with respiratory symptoms, or tested positive. They should be able to consent, complete surveys/assessments, follow up on visits, and use birth control if applicable.
What is being tested?
The RECOVER-SLEEP trial tests multiple treatments for post-COVID sleep issues: Melatonin, Modafinil, Solriamfetol and Tailored lighting (TL), each against a placebo. It's multi-center and randomized; patients don't choose their treatment.
What are the potential side effects?
Possible side effects include headaches, dizziness from melatonin; insomnia, anxiety from modafinil; heart palpitations from solriamfetol; no significant side effects expected from tailored lighting but may vary individually.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Total number of participants enrolled in each Appendix

Trial Design

2Treatment groups
Experimental Treatment
Group I: Hypersomnia Arm (Appendix A)Experimental Treatment4 Interventions
This is a double-blind, phase 2, randomized, placebo-controlled interventional trial of a wake-promoting drug (modafinil or solriamfetol) to treat hypersomnia, defined by elevated scores (\> 60) on the PROMIS 8a SRI scale, in participants with PASC. Participants will be randomized to study drug or control. Participants who meet the eligibility criteria for modafinil will receive either active modafinil or modafinil-matched control. If modafinil is contraindicated, participants will be assessed for solriamfetol. If participants are eligible for solriamfetol, they will receive either active solriamfetol or solriamfetol-matched control. If solriamfetol is contraindicated, participants will be excluded from Appendix A. Modafinil and solriamfetol will be analyzed as a single wake-promoting drug condition versus control. The intervention duration will be 10 weeks. Anticipated enrollment is 474 participants. Details about the Hypersomnia Appendix are available under NCT06404099.
Group II: Complex PASC related Sleep Disturbances (CPSD) Arm (Appendix B )Experimental Treatment4 Interventions
This is a double-blind, phase 2, randomized, placebo-controlled, interventional trial that combines brief education and a tailored sleep timing prescription for CPSD with therapies that modify circadian timing for participants who report poor sleep quality or daytime sleep-related impairment, defined by elevated scores (≥60) on the PROMIS 8b SD scale, in participants with symptoms that occurred or worsened after COVID-19 infection. Interventions involve tailored lighting (TL) and melatonin. Participants will be randomly assigned to 1 of 4 groups: (a) active TL + oral melatonin, (b) active TL + placebo melatonin, (c) placebo TL + oral melatonin, and (d) placebo TL + placebo melatonin. All groups will receive BBT-CPSD. It is a 2x2 factorial design schema. The intervention duration will be 8 weeks. Anticipated enrollment for this appendix is 600 participants. Additional details about the CPSD Appendix are available under NCT06404112.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Melatonin
2014
Completed Phase 4
~1150
Modafinil
2002
Completed Phase 4
~1700
Modafinil Placebo
2018
Completed Phase 1
~20
Solriamfetol
2021
Completed Phase 4
~60

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,424 Previous Clinical Trials
3,065,010 Total Patients Enrolled
Christina Barkauskas, MDStudy ChairDuke Clinical Research Institute
3 Previous Clinical Trials
1,074 Total Patients Enrolled
Susan Redline, MD MPHStudy ChairBrigham and Women's Hospital
2 Previous Clinical Trials
1,074 Total Patients Enrolled
~716 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top